Dupilumab is a monoclonal antibody with a molecular weight of about 147000 Da. Because of this characteristic, chemical and physical characteristics are not applicable for this compound. Dupilumab is a fully human monoclonal antibody of the immunoglobulin (Ig)G4 subclass that binds to the interleukin (IL)-4 receptor. It was first approved by the Food and Drug Administration (FDA) in 2017. It is currently used to treat atopic dermatitis (AD), asthma as an add-on maintenance treatment, chronic rhinosinusitis with nasal polyposis (CRSwNP), and eosinophilic esophagitis (EoE). It is used as monotherapy or in combination with other drugs, such as corticosteroids.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Dupilumab, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.